论文部分内容阅读
目的:探讨BRMS1的表达与乳腺癌腋窝淋巴结微转移的关系。方法:采用连续切片和CK-19联合检测86例腋窝淋巴结转移阴性的所有淋巴结微转移灶的情况,术后随访其复发情况,免疫组化检测乳腺癌组织中BRMS1的表达并分析其与淋巴结微转移及术后复发率的关系。结果:86例乳腺癌腋窝淋巴结转移阴性的689淋巴结中有48粒(6.97%)检测到微转移,其中阳性病例22例(25.58%),BRMS1的表达阴性的乳腺癌患者腋窝淋巴结微转移病例率(43.24%)和术后复发率(54.05%)远高于BRMS1表达阳性的乳腺癌患者(12.24%,8.16%),差异具有显著性,且呈明显的负相关。结论:BRMS1与腋窝淋巴结微转移密切相关,可以成为乳腺癌腋窝淋巴结微转移分子指标,并对乳腺癌的分期、预后、治疗具有重要的指导意义。
Objective: To investigate the relationship between BRMS1 expression and axillary lymph node micrometastasis in breast cancer. Methods: All the lymph node micrometastases in 86 cases with negative axillary lymph node metastasis were detected by serial sections and CK-19. The recurrence was observed after operation. The expression of BRMS1 in breast cancer tissues was detected by immunohistochemistry and analyzed with lymph node microglia Metastasis and postoperative recurrence rate. RESULTS: Micrometastases were detected in 48 out of 86 breast cancer patients with axillary lymph node metastasis negative in 689 (6.97%), of which 22 were positive (25.58%). The incidence of axillary lymph node micrometastases in BRMS1 negative breast cancer patients (43.24%) and postoperative recurrence rate (54.05%) were significantly higher than those in BRMS1 positive breast cancer patients (12.24%, 8.16%). The difference was significant and negatively correlated. CONCLUSION: BRMS1 is closely related to micrometastasis of axillary lymph nodes and may be used as a molecular marker of axillary lymph node micrometastasis in breast cancer. It has important guiding significance for staging, prognosis and treatment of breast cancer.